VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

We recently compiled a list of the Billionaire Ken Fisher's Top 10 High Growth Stock Picks. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the ...

Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a market cap of $385.16 billion, a P/E ratio of 27.78, a PEG ratio of 0.93 and a beta of 0.45.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk A/S Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...